Jason Gerberry
BofA Securities, Research Division

We're going to get going here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I cover biotech and pharma and I'm pleased to be introducing Xenon Pharmaceuticals and Tucker Kelly, CFO. So Tucker, thanks for joining us.

Thomas Kelly
Chief Financial Officer

Great. Jason, wonderful to be here in Vegas with you and the BofA team and appreciate the opportunity.

Jason Gerberry
BofA Securities, Research Division

Great. So maybe we'll start with just azetukalner for FOS epilepsy. You recently had your confirmatory pivotal study and next step is going to be regulatory. But maybe just at a high level, how would you -- coming out of that data, say the elevator hook is looking for azetukalner in the ASM space. There's a lot of different ASM alternatives. So maybe if you could just sort of frame the why and then we can go from there.

Thomas Kelly
Chief Financial Officer

Yes, absolutely. So we were really excited when we reported out in March, the second, as you say, of our pivotal studies for azetukalner in focal onset seizures. So this is the X-TOLE2 study, which had a tremendous result, largest median percent change in seizure frequency on a placebo-adjusted basis ever seen in a registration study. And helpfully as well, it was incredibly confirmatory of the initial X-TOLE2 study -- the X-TOLE study we had done in the Phase IIb. So the efficacy, the safety, all the metrics that you really care about were incredibly consistent with what we've seen before. So we think we've got a really great drug on our hands. As you